Nutrition 21 Diachrome, Zeramax Sales To Be Backed By Research Initiatives
This article was originally published in The Tan Sheet
Executive Summary
Nutrition 21 plans to support the broad launch of its Diachrome chromium picolinate/biotin blend with a relatively large-scale clinical study, according to President and CEO Gail Montgomery
You may also be interested in...
Nutrition 21
Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...
Nutrition 21
Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...
Nutrition 21
Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...